Sinopharm Group (HKG:1099) has renewed five existing agreements with its controlling shareholder, China National Pharmaceutical Group Corp., for three years ahead of their expiry, according to a Monday bourse filing.
The company said it will continue procuring and selling CNPGC's products, as well as utilizing its EPC general contracting, factoring, and financial services from 2027 through 2029.